ArticleDiscover oncology2025
Prognostic value of lymphocyte to C‑reactive protein ratio in resectable esophageal squamous cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lymphocyte to C-reactive protein ratio (LCR), recognized as a novel inflammatory marker, has exhibited prognostic relevance across diverse malignant tumors. However, investigations regarding its prognostic significance in esophageal squamous cell carcinoma (ESCC) remain scarce. In this investigation, 914 individuals with ESCC who underwent radical surgical intervention were retrospectively analyzed to evaluate the correlation between LCR and clinicopathological characteristics, as well as overall survival (OS). The findings indicated that individuals classified within the low LCR group displayed markedly elevated proportions of T3/T4a stages, stage III disease, and increased inflammatory markers. Survival analyses demonstrated that diminished LCR was significantly associated with reduced 3-year and 5-year OS, while multivariate Cox regression analysis established LCR as an independent prognostic indicator. A predictive nomogram integrating LCR with tumor-node-metastasis (TNM) staging yielded a superior area under the curve values for 3-year and 5-year OS prediction compared to TNM staging alone. These results suggest that LCR functions as an independent prognostic parameter for postoperative ESCC, and that the combined nomogram model incorporating LCR and TNM staging may offer a refined tool for individualized clinical survival evaluation. The observed association between reduced LCR levels and both tumor progression and systemic inflammation implies potential therapeutic implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.